MULTIPLE myeloma ICU survival has improved in recent years, with better adjusted one year outcomes despite greater illness ...
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according ...
Population-level trends and geographic disparities in pancreatic cancer mortality among individuals with psychoactive substance use disorders: A retrospective analysis. This is an ASCO Meeting ...
Patients with multiple myeloma who received a new immunotherapy combination lived significantly longer without their cancer worsening and showed early signs of improved survival in a large ...
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...
By Dennis Thompson HealthDay ReporterWEDNESDAY, June 3, 2026 (HealthDay News) — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into ...
This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.
Atrial fibrillation (AF) is a relatively frequent complication after autologous stem cell transplantation in patients with multiple myeloma, one that’s associated with an increased risk of mortality, ...
January 13, 2009 — Tandem autologous hematopoietic cell transplantation (AHCT) does not appear to improve overall survival or event-free survival in patients with multiple myeloma, according to a meta ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results